Letters

O'Mahony JF. Comment on Keeney et al.’s “Delphi Analysis of Relevant Comparators in a Cost‑Effectiveness Model of Prostate Cancer Screening”. PharmacoEconomics, 2021, https://doi.org/10.1007/s40273-021-01061-2.

O'Mahony JF. HIQA’s Perspective on the Challenges Posed by Evaluations of Screening Programs: A Reply. Value in Health, 2019, 22(1), https://doi.org/10.1016/j.jval.2018.06.021.

McFerran E, O'Mahony JF, Fallis R, McVicar D, Zauber AG and Kee F, Evaluation of the Effectiveness and Cost-Effectiveness of Personalized Surveillance After Colorectal Adenomatous Polypectomy, Epidemiologic Reviews, 2017, DOI https://doi.org/10.1093/epirev/mxx002.

O'Mahony JF. Cost-Effectiveness Estimates: the Need for Complete Reporting.The Lancet Public Health, 2017 May 31;2(5):e211, DOI: 10.1016/S2468-2667(17)30073-7.

Masterson L, O'Mahony JF and Lechner M, Expanding the Benefits of HPV Vaccination to Boys and Men. The Lancet, 2016, 388(10063), p.2992.

Paulden M, O'Mahony JF, Culyer AJ, & McCabe C. Objectivity and Equity: Clarity Required. A Response to Hill and Olson, PharmacoEconomics, 2014, 32(12), p1249-50.

O'Mahony JF. Cost-Effectiveness of Population-Based Screening for Colorectal Cancer, The British Journal of Cancer, 2013 Mar 19;108(5):1209.

O’Mahony JF. Re: Cost-Effectiveness of Pertussis Booster Vaccination in the Netherlands, Vaccine, 2012 Nov, 26;30(50):7141.